title: What can the European Multicenter Trial on the treatment of Graves' disease with antithyroid drugs teach us about the course of thyroid-associated orbitopathy (TAO)? European Multicenter Trial Group.
authors.affiliation: Merck KGaA, Department CRDO/DS Darmstadt, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Benker
authors.forename: G J
authors.initials: GJ
authors.lastname: Kahaly
authors.forename: D
authors.initials: D
authors.lastname: Reinwein
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology; D013956:Antithyroid Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005139:Eyeglasses; D006111:Graves Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D015995:Prevalence
chemical_list: D013956:Antithyroid Agents